not1 Antibody

What is the NOT1 protein and why is it important in research?

NOT1 (also known as CNOT1) is the largest subunit of the CCR4-NOT complex, functioning as a scaffold protein that mediates transcriptional regulation and RNA metabolism. The human version of NOT1 has a canonical length of 2376 amino acids and a molecular weight of approximately 266.9 kilodaltons . It's localized in both the nucleus and cytoplasm, and is widely expressed across multiple tissue types. Research interest in NOT1 stems from its critical roles in mRNA deadenylation, transcriptional regulation, and trophectodermal cell differentiation, making it relevant to studies of gene expression control and developmental biology .

What alternative names should I know when searching for NOT1 antibodies?

When searching literature or antibody catalogs, researchers should be aware that NOT1 is also referred to by several synonyms:

• CNOT1 (CCR4-NOT transcription complex subunit 1)

• AD-005

• CDC39

• HPE12

Understanding these alternative designations is essential when conducting literature searches or selecting appropriate antibodies for your research applications.

What are the main applications for NOT1 antibodies in research?

NOT1 antibodies are predominantly used in the following applications:

• Western blotting for protein detection and quantification

• ELISA for quantitative measurement of NOT1 levels

• Immunohistochemistry for cellular localization studies

When selecting a NOT1 antibody, verify that it has been validated for your specific application, as antibody performance can vary significantly between different experimental contexts .

How should I validate the specificity of a NOT1 antibody for my research?

Proper validation of NOT1 antibodies should follow the five pillars approach recommended by the International Working Group for Antibody Validation (IWGAV):

• Orthogonal methods: Compare antibody-based results with antibody-independent methods such as mass spectrometry

• Genetic knockdown: Verify reduced signal following siRNA/shRNA knockdown of NOT1

• Recombinant expression: Test antibody recognition of overexpressed NOT1 protein

• Independent antibodies: Confirm results using multiple antibodies targeting different epitopes

• Capture mass spectrometry: Analyze antibody-captured proteins to confirm specificity

These validation methods are particularly important for NOT1 research, as non-specific binding to other components of the CCR4-NOT complex could lead to misinterpretation of results.

What criteria should I use when selecting between polyclonal and monoclonal NOT1 antibodies?

For NOT1 research, polyclonal antibodies may be preferred for initial detection studies due to their higher sensitivity, while monoclonal antibodies are better suited for quantitative analyses requiring high reproducibility .

How can I verify that my NOT1 antibody is detecting the correct isoform?

NOT1 exists in multiple isoforms (at least 4 have been identified in humans) . To verify isoform-specific detection:

• Control experiments: Use recombinant expression of specific isoforms

• Western blot analysis: Confirm the molecular weight matches your target isoform

• Sequencing: When possible, sequence the immunoprecipitated protein

• Isoform-specific knockdown: Use siRNAs targeting unique regions of specific isoforms

• Epitope mapping: Determine which region of NOT1 your antibody recognizes

Document the specific isoform recognized by your antibody in your methods section, as different isoforms may have distinct functions or localizations.

What are the optimal conditions for using NOT1 antibodies in Western blotting?

For successful Western blotting with NOT1 antibodies, consider these methodological optimizations:

• Sample preparation: Given NOT1's high molecular weight (266.9 kDa), use lower percentage gels (6-8%) or gradient gels

• Transfer conditions: Extended transfer times (overnight at low voltage) improve transfer efficiency of large proteins

• Blocking agents: 5% BSA in TBST often provides better results than milk-based blockers

• Primary antibody dilution: Typically 1:500 to 1:2000, but always optimize based on the specific antibody

• Detection system: HRP-conjugated secondary antibodies with enhanced chemiluminescence provide good sensitivity

Always include positive controls (tissues/cells known to express NOT1) and negative controls (tissues/cells with low expression or NOT1 knockdown samples) .

How should I approach co-immunoprecipitation studies of NOT1 and its interaction partners?

When investigating NOT1 protein interactions through co-immunoprecipitation:

• Lysis buffer selection: Use buffers with moderate ionic strength (150-300 mM NaCl) and mild detergents (0.5-1% NP-40 or Triton X-100)

• Cross-linking: Consider gentle cross-linking with DSP or formaldehyde to preserve transient interactions

• Antibody orientation: Test both direct NOT1 immunoprecipitation and reverse IP of suspected interaction partners

• Controls: Include IgG controls and, when possible, NOT1 knockdown samples

• Elution strategy: Use gentle elution with peptide competition or low pH buffers to preserve interaction integrity

When analyzing results, be aware that NOT1 functions as a scaffold protein in the CCR4-NOT complex, so numerous interactions may be detected .

What considerations are important when using NOT1 antibodies for immunohistochemistry?

For successful immunohistochemistry with NOT1 antibodies:

• Fixation: Typically, 4% paraformaldehyde works well, but optimize for your specific tissue

• Antigen retrieval: Heat-induced epitope retrieval using citrate buffer (pH 6.0) is often effective

• Blocking: Use 5-10% normal serum from the same species as the secondary antibody

• Primary antibody incubation: Overnight at 4°C at optimized dilution (typically 1:100 to 1:500)

• Signal amplification: Consider tyramide signal amplification for enhanced sensitivity

• Controls: Include positive control tissues and negative controls (primary antibody omission)

Remember that NOT1 is expressed in both nucleus and cytoplasm, so the expected staining pattern should reflect this dual localization .

How can I address non-specific binding when using NOT1 antibodies?

Non-specific binding is a common challenge with NOT1 antibodies. Implement these strategies to improve specificity:

• Increase blocking time/concentration: Try 5% BSA or 10% normal serum from the species of your secondary antibody

• Optimize antibody concentration: Perform titration experiments to find the optimal concentration

• Increase washing steps: Add additional washes with higher salt concentration (up to 500 mM NaCl)

• Pre-absorb the antibody: Incubate with negative control lysates to remove cross-reactive antibodies

• Use alternative detection systems: Switch from colorimetric to fluorescent detection for lower background

Additionally, validate specificity using genetic approaches such as CNOT1 knockdown or knockout controls to confirm signal specificity .

What strategies can help detect low abundance NOT1 protein in certain tissues or cellular compartments?

Detecting low abundance NOT1 protein requires sensitivity-enhancing techniques:

• Sample enrichment: Use subcellular fractionation to concentrate the compartment of interest

• Signal amplification: Employ tyramide signal amplification or polymer-based detection systems

• Enhanced chemiluminescence: Use high-sensitivity ECL substrates for Western blotting

• Increased antibody incubation time: Extend primary antibody incubation to overnight at 4°C

• Concentrated lysates: Load more protein (50-100 μg) per lane for Western blotting

• Immunoprecipitation: Concentrate the protein prior to detection

For quantitative applications, consider using ELISA-based methods with signal amplification to detect low levels of NOT1 protein .

How should I troubleshoot issues with reproducibility in NOT1 antibody experiments?

Reproducibility challenges with NOT1 antibodies can be addressed through systematic troubleshooting:

• Antibody storage: Aliquot antibodies and avoid freeze-thaw cycles

• Lot-to-lot variation: Document lot numbers and test new lots against previous ones

• Protocol standardization: Create detailed protocols with precisely defined conditions

• Positive controls: Always include known positive samples in each experiment

• Environmental factors: Control temperature, humidity, and incubation times precisely

• Data normalization: Use internal controls (housekeeping proteins) consistently

For critical experiments, consider using two different NOT1 antibodies targeting different epitopes to confirm results, following the independent antibody validation principle .

How can I differentiate between phosphorylated and non-phosphorylated forms of NOT1 protein?

Distinguishing phosphorylation states of NOT1 requires specialized approaches:

• Phospho-specific antibodies: Use antibodies specifically raised against known NOT1 phosphorylation sites

• Phosphatase treatment: Compare samples with and without phosphatase treatment

• Phos-tag SDS-PAGE: Use Phos-tag acrylamide gels to separate phosphorylated proteins

• 2D gel electrophoresis: Separate proteins based on isoelectric point and molecular weight

• Mass spectrometry: For definitive phosphosite identification and quantification

When interpreting results, remember that phosphorylation may affect NOT1's interactions within the CCR4-NOT complex and its subcellular localization .

What approaches can be used to study NOT1 in the context of protein complexes?

Investigating NOT1 within its native protein complexes requires specialized methods:

• Blue Native PAGE: Separate intact protein complexes under non-denaturing conditions

• Size-exclusion chromatography: Fractionate complexes based on size prior to immunodetection

• Multi-antibody co-IP: Use antibodies against multiple components of the CCR4-NOT complex

• Proximity ligation assay: Visualize protein-protein interactions in situ

• Cross-linking mass spectrometry: Identify interaction interfaces within the complex

These approaches provide insights into NOT1's scaffold function within the CCR4-NOT complex and help elucidate how complex assembly affects cellular functions .

How can emerging antibody technologies be applied to NOT1 research?

Recent technological advances offer new possibilities for NOT1 research:

• Single-domain antibodies (nanobodies): Smaller size allows access to restricted epitopes and improved tissue penetration

• Recombinant antibody fragments: Engineered for specific applications like super-resolution microscopy

• Computationally designed antibodies: Systems like JAM enable de novo design of antibodies with therapeutic-grade properties

• Bi-specific antibodies: Target NOT1 and its interaction partners simultaneously

• Intrabodies: Express within cells to track or modulate NOT1 function in living systems

These technologies may overcome limitations of traditional antibodies, particularly for accessing epitopes within large protein complexes like those involving NOT1 .